Takeda Continues Post-patent Prevacid Hit, Looks Externally For Innovation And Leadership
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Takeda, like most Japanese pharma, is hoping to counter the ongoing trend of patent expirations and yen appreciation by looking outward. Pushing beyond their comfort zones of Japan and U.S. markets, Japan's top pharma are pushing to gain ground in Europe and Asia. Similarly, these companies are looking outside of their own staff for expertise in these new regions
You may also be interested in...
Takeda CEO Calls For A Paradigm Shift In Japanese R&D; BIO Japan Conference Takeaway Message, Head West...To China
Hasegawa encouraged Japanese companies to embrace a paradigm shift in their approach to R&D, which includes being open to reverse innovation and rethinking how global R&D can be localized
Takeda CEO Calls For A Paradigm Shift In Japanese R&D; BIO Japan Conference Takeaway Message, Head West...To China
Hasegawa encouraged Japanese companies to embrace a paradigm shift in their approach to R&D, which includes being open to reverse innovation and rethinking how global R&D can be localized
Takeda CEO Calls For A Paradigm Shift In Japanese R&D; BIO Japan Conference Takeaway Message, Head West...To China
YOKOHAMA, Japan - Takeda Pharmaceutical Co. CEO Yasuchika Hasegawa encouraged his fellow Japanese companies to embrace a paradigm shift in their approach to R&D, which includes being open to reverse innovation and rethinking how global R&D can be localized